A Phase 3 Double-blind Placebo-controlled Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy with DBV712 250 g in 4-7-year-old Children with Peanut Allergy

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Peanut Allergy
  • Age: Between 4 Year(s) - 7 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Age: Between 4-7 years
    2. Gender: Male or Female
    3. Physician-diagnosed peanut allergy
    4. Currently following a strict peanut-free diet
    5. Serum peanut-specific IgE > 0.7 kUA/L and a positive peanut skin prick test

You may not be eligible for this study if the following are true:

    1. You are participating in current immunotherapy for any allergen (including food allergy, allergic rhinitis and/or insect allergy)
    2. Past history of very severe anaphylaxis to peanut
    3. Inability to stop short-acting or long-acting antihistamines for a minimum washout period
    4. Diagnosed with poorly or uncontrolled asthma
    5. Have a history of any immunotherapy for peanut allergy, including EPIT, OIT, SLIT

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.